Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 13/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.57 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.57 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.57 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4687732 | 0.90 | PARP10 (0.68) | PARP10GAAPARP15PARP4ALDH1A1 | |
| SCHEMBL17919521 | 0.89 | PARP10 (0.67) | PARP10GAAPARP15PARP4ALDH1A1 | |
| SCHEMBL19389670 | 0.89 | PARP10 (0.67) | PARP10GAAPARP15PARP4ALDH1A1 | |
| SCHEMBL4652331 | 0.87 | PARP10 (0.64) | PARP10GAAPARP15PARP4ALDH1A1 | |
| SCHEMBL27295340 | 0.87 | PARP10 (0.64) | PARP10GAAPARP15PARP4ALDH1A1 | |
| SCHEMBL4654822 | 0.87 | PARP10 (0.64) | PARP10GAAPARP15PARP4ALDH1A1 | |
| SCHEMBL4652513 | 0.87 | PARP10 (0.64) | PARP10GAAPARP15PARP4ALDH1A1 | |
| SCHEMBL4687508 | 0.86 | PARP10 (0.68) | PARP10PARP15PARP4ALDH1A1KMT2A | |
| SCHEMBL6122034 | 0.84 | PARP10 (0.70) | PARP10PARP15PARP4ALDH1A1KMT2A | |
| SCHEMBL17324196 | 0.83 | GAA (0.67) | PARP10GAAALDH1A1NR1I2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121421-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | Novartis AG (CH) | 2023-01-25 | — | — | EP | claimed |
| WO-2021186324-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2021-09-23 | — | — | WO | claimed |
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | claimed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2340021-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | claimed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| WO-2010031713-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | claimed |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | DING QINGJIE | 2010-03-25 | — | — | US | claimed |
| EP-1805163-B1 | 1,1A,5,5A-TETRAHYDRO-3-THIA-CYCLOPROPA[A]PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-10-01 | — | — | EP | claimed |
| JP-6087794-A | — | — | None | — | — | JP | disclosed |
| JP-5125028-A | — | — | None | — | — | JP | disclosed |
| EP-4395769-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023031781-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2023-03-09 | — | — | WO | disclosed |
| EP-4121421-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | Novartis AG (CH) | 2023-01-25 | — | — | EP | disclosed |
| EP-1974946-A1 | Thermal transfer image-receiving sheet and surface condition improver | FUJIFILM Corporation (JP) | 2008-10-01 | — | — | EP | disclosed |
| JP-H0687794-A | PRODUCTION OF ESTER | YOTSUKAICHI GOSEI KK | 1994-03-29 | — | — | JP | disclosed |
| JP-H05125028-A | PRODUCTION OF CARBONIC ACID ESTER | YOTSUKAICHI GOSEI KK | 1993-05-21 | — | — | JP | disclosed |
| US-4983502-A | Exposing and developing material containing specific heat solvent | KONICA CORPORATION (JP) | 1991-01-08 | — | — | US | disclosed |
| EP-0330478-A2 | A heat developing photosensitive material | KONICA CORPORATION (JP) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | PARP10 74/4885GAA 2654/4885PARP15 72/4885 |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | PARP10 74/4885GAA 2654/4885PARP15 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.